Use of a New Monoclonal Antibody-Based Enzyme Immunoassay for Soluble Fibrin to Exclude Pulmonary Embolism

Summary

We prospectively evaluated the diagnostic performance of a new soluble fibrin assay in 303 consecutive patients with suspected pulmonary embolism and examined potentially useful cut-off levels at which this disease can be safely excluded. In addition, the diagnostic accuracy was calculated in the subgroups of in- and outpatients. The ROC curve of the assay in the total study cohort had an area under the curve of 0.69. The cut-off level associated with a sensitivity and negative predictive value of 100% was 20 ng/ml, but the specificity was only 4%. The cut-off level with a sensitivity of 90% was 30 ng/ml, which corresponded with a specificity and negative predictive value of 27% and 86%, respectively. The diagnostic performance was comparable in the subgroups of in- and outpatients. We conclude that the soluble fibrin assay has a low diagnostic accuracy and seems unsuitable as a screening test for the exclusion of pulmonary embolism.

Key words

Soluble fibrin - pulmonary embolism - diagnosis

^* Study investigators are listed in the appendix

• References

• 1 Doolittle RF. Fibrinogen and fibrin. Sci Am 1981; 245: 92-101.
• 2 Sasaki T, Page IH, Shainoff JR. Soluble complexes of fibrinogen and fibrin. Science 1966; 152: 1069-71.
• 3 Alkajersig N, Fletcher AP. Formation of soluble fibrin oligomers in purified system and in plasma. Biochem J 1983; 213: 75-83.
• 4 Demers C, Ginsberg JS, Johnston M, Brill-Edwards P, Panju P. D-dimer and thrombin-antithrombin III complexes in patients with clinically suspected pulmonary embolism. Thromb Haemost 1992; 67: 408-12.
• 5 Ginsberg JS, Siragusa S, Douketis J, Johnston M, Moffat K, Donovan D, McGinnis J, Brill-Edwards P, Panju A, Patel A, Weitz JI. Evaluation of a soluble fibrin assay in patients with suspected pulmonary embolism. Thromb Haemost 1996; 75: 551-4.
• 6 Reber G, Bounameaux H, Perrier A, de Moerloose Ph. Performances of the fibrin monomer test for the exclusion of pulmonary embolism in symptomatic outpatients. Thromb Haemost 1999; 81: 221-3.
• 7 Bos R, Laterveer-Vreeswijk GH, Lockwood D, Szewczyk K, Nieuwenhuizen W. A new enzyme immunoassay for soluble fibrin in plasma, with a high discriminating power for thrombotic disorders. Thromb Haemost 1999; 81: 54-9.
• 8 Hull RD, Hirsh J, Carter CJ, Raskob GE, Gill GJ, Jay RM, Leclerc JR, David M, Coates G. Diagnostic value of ventilation-perfusion long scanning in patients with suspected pulmonary embolism. Chest 1985; 88: 819-28.
• 9 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristics curve. Radiology 1982; 143: 29-36.
• 10 Takahashi H, Wada K, Hanano M, Niwano H, Takizawa S, Yazawa Y, Shibata A. Fibrinolysis and fibrinogenolysis in patients with thrombotic disease. Blood Coagul Fibrinolysis 1992; 03: 193-6.
• 11 Dempfle C-E. The use of soluble fibrin in evaluating the acute and hypercoagulable state. Thromb Haemost 1999; 82: 673-83.